Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor

Trial Profile

Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor

Phase of Trial: Phase I

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Tegatrabetan (Primary)
  • Indications Fibroma
  • Focus Adverse reactions; First in man
  • Sponsors Iterion Therapeutics
  • Most Recent Events

    • 05 Dec 2018 According to an Iterion Therapeutics media release, the trial is being funded with proceeds from Sante Ventures that included GOOSE Society and AngelMD and a grant from the Cancer Prevention Research Institute of Texas (CPRIT).
    • 24 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top